Welcome to our dedicated page for Alumis SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering Alumis Inc. (ALMS) biotech disclosures often means wading through TYK2 pathways, safety data tables, and funding footnotes—hardly light reading. If you’ve ever searched for “Alumis SEC filings explained simply,” you know the struggle. Pipeline timelines for ESK-001 and A-005, cash-runway projections, and dilution risks hide inside dense language spread over hundreds of pages.
Stock Titan solves that problem. Our AI-powered summaries convert every Alumis quarterly earnings report 10-Q filing and Alumis annual report 10-K simplified into clear, actionable insights. Instantly surface R&D spend, trial-readout dates, or liquidity trends, then jump straight to the cited paragraph. Need real-time alerts? We deliver Alumis Form 4 insider transactions real-time so you can spot unusual Alumis executive stock transactions Form 4 minutes after they hit EDGAR. You’ll also receive push notifications when an Alumis 8-K material events explained or the next Alumis proxy statement executive compensation is posted.
Whether you’re modeling future raises, evaluating precision oral therapies, or understanding Alumis SEC documents with AI, every filing type is here—10-K, 10-Q, S-1, S-8, 13D/G—alongside Alumis earnings report filing analysis that compares quarter-over-quarter burn. Common questions like “Where can I find Alumis insider trading Form 4 transactions?” or “How to interpret a TYK2 trial update?” are answered alongside source links, letting you focus on decisions, not document hunts.
- Monitor clinical-trial milestone disclosures in seconds
- Compare R&D spend and cash runway across quarters
- Track insider moves before the market reacts
Complex filings, clarified—so you never miss a detail.
Alumis Inc. reported Q3 2025 results showing a net loss of $110.8 million as R&D spending of $97.8 million and G&A of $19.5 million outweighed $2.1 million of collaboration revenue. For the nine months, total revenue was $22.1 million (license $17.4 million; collaboration $4.7 million), and net loss was $150.4 million, reflecting a $187.9 million gain on bargain purchase from the ACELYRIN merger.
The company completed the ACELYRIN Merger on May 21, 2025, issuing 48,653,549 shares as consideration of $238.1 million for net assets with a fair value of $426.0 million, and recognized a $10.7 million deferred tax liability tied to acquired IPR&D.
As of September 30, 2025, cash and cash equivalents were $65.3 million and marketable securities were $312.5 million; stockholders’ equity was $384.8 million. Operating cash outflow for the nine months was $297.6 million. Management states the $377.7 million in cash, cash equivalents and marketable securities provides at least 12 months of funding. As of November 6, 2025, voting shares outstanding were 97,208,495 and non‑voting shares were 7,184,908.
Alumis Inc. completed the ACELYRIN merger and significantly strengthened its balance sheet. Total assets rose to $610.9 million from $341.0 million at year-end, and combined cash, cash equivalents and marketable securities totaled approximately $486.3 million as of June 30, 2025. The company issued 48,653,549 shares (about $238.1 million consideration) to acquire ACELYRIN, adding the lonigutamab program and an IPR&D intangible asset valued at ~$51.0 million. The acquisition produced a $187.9 million gain on bargain purchase, which turned the quarter to a $59.3 million net income result.
Operationally Alumis remains a development-stage, cash-consuming biopharma. Revenue was $2.7 million for the quarter ($20.1 million six months) while research and development expense rose to $108.8 million in the quarter and operating cash used was $186.7 million for the six months. The company had an accumulated deficit of $698.2 million and states existing resources should fund operations for at least 12 months, though additional capital will be needed thereafter.
Alumis Inc. furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states that the information in Item 2.02 and Exhibit 99.1 is furnished and therefore is not deemed to be "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The report is signed by Martin Babler, President and Chief Executive Officer.
FAQ
What is the current stock price of Alumis (ALMS)?
What is the market cap of Alumis (ALMS)?
